GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marizyme Inc (OTCPK:MRZM) » Definitions » Piotroski F-Score

MRZM (Marizyme) Piotroski F-Score : 3 (As of Sep. 24, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Marizyme Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Marizyme has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Marizyme's Piotroski F-Score or its related term are showing as below:

MRZM' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 3   Max: 7
Current: 3

During the past 13 years, the highest Piotroski F-Score of Marizyme was 7. The lowest was 2. And the median was 3.


Marizyme Piotroski F-Score Historical Data

The historical data trend for Marizyme's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marizyme Piotroski F-Score Chart

Marizyme Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 3.00 3.00 2.00 3.00

Marizyme Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 3.00 3.00 3.00

Competitive Comparison of Marizyme's Piotroski F-Score

For the Biotechnology subindustry, Marizyme's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marizyme's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marizyme's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Marizyme's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun24) TTM:Last Year (Jun23) TTM:
Net Income was -32.45 + -9.766 + -6.226 + -4.073 = $-52.52 Mil.
Cash Flow from Operations was -1.153 + -1.214 + -0.809 + -0.733 = $-3.91 Mil.
Revenue was 0.182 + 0.151 + 0.033 + 0 = $0.37 Mil.
Gross Profit was 0.131 + 0.102 + 0.023 + 0 = $0.26 Mil.
Average Total Assets from the begining of this year (Jun23)
to the end of this year (Jun24) was
(36.981 + 36.92 + 22.015 + 21.57 + 21.535) / 5 = $27.8042 Mil.
Total Assets at the begining of this year (Jun23) was $36.98 Mil.
Long-Term Debt & Capital Lease Obligation was $0.46 Mil.
Total Current Assets was $0.92 Mil.
Total Current Liabilities was $23.55 Mil.
Net Income was -1.553 + -23.564 + -2.555 + -20.576 = $-48.25 Mil.

Revenue was 0.076 + 0.096 + 0.129 + 0.185 = $0.49 Mil.
Gross Profit was 0.061 + 0.068 + 0.09 + 0.135 = $0.35 Mil.
Average Total Assets from the begining of last year (Jun22)
to the end of last year (Jun23) was
(64.3 + 63.726 + 38.688 + 38.27 + 36.981) / 5 = $48.393 Mil.
Total Assets at the begining of last year (Jun22) was $64.30 Mil.
Long-Term Debt & Capital Lease Obligation was $1.17 Mil.
Total Current Assets was $1.06 Mil.
Total Current Liabilities was $20.82 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Marizyme's current Net Income (TTM) was -52.52. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Marizyme's current Cash Flow from Operations (TTM) was -3.91. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun23)
=-52.515/36.981
=-1.42005354

ROA (Last Year)=Net Income/Total Assets (Jun22)
=-48.248/64.3
=-0.7503577

Marizyme's return on assets of this year was -1.42005354. Marizyme's return on assets of last year was -0.7503577. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Marizyme's current Net Income (TTM) was -52.52. Marizyme's current Cash Flow from Operations (TTM) was -3.91. ==> -3.91 > -52.52 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun23 to Jun24
=0.46/27.8042
=0.01654426

Gearing (Last Year: Jun23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun22 to Jun23
=1.173/48.393
=0.02423904

Marizyme's gearing of this year was 0.01654426. Marizyme's gearing of last year was 0.02423904. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun24)=Total Current Assets/Total Current Liabilities
=0.922/23.552
=0.03914742

Current Ratio (Last Year: Jun23)=Total Current Assets/Total Current Liabilities
=1.059/20.822
=0.05085967

Marizyme's current ratio of this year was 0.03914742. Marizyme's current ratio of last year was 0.05085967. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Marizyme's number of shares in issue this year was 131.793. Marizyme's number of shares in issue last year was 43.187. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.256/0.366
=0.69945355

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.354/0.486
=0.72839506

Marizyme's gross margin of this year was 0.69945355. Marizyme's gross margin of last year was 0.72839506. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun23)
=0.366/36.981
=0.00989697

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun22)
=0.486/64.3
=0.00755832

Marizyme's asset turnover of this year was 0.00989697. Marizyme's asset turnover of last year was 0.00755832. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+0+0+1
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Marizyme has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Marizyme  (OTCPK:MRZM) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Marizyme Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Marizyme's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Marizyme Business Description

Traded in Other Exchanges
N/A
Address
555 Heritage Drive, Suite 205, Jupiter, FL, USA, 33458
Marizyme Inc is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical device technologies that improve patient health outcomes. Currently, the company is focused on developing three medical technology products: DuraGraft, Krillase, and MATLOC. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, MATLOC is a point-of-care, lab-on-chip digital screening, and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment, and Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health.
Executives
Braeden Lichti 10 percent owner 650 GEORGIA ST #3200, VANCOUVER A1 V6B4P7
Nilesh Umedbhai Patel director 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Michael R Stewart director 5 WALNUT GROVE DRIVE, STE 140, HORSHAM PA 19044
Harrison Ross officer: Vice President of Finance 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Georgiy Kovalyov officer: Chief Financial Officer 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
David Barthel director, officer: Chief Executive Officer 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Bradley Richmond officer: Acting VP of Finance 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Julie B. Kampf director 14054 OLD CYPRESS BEND, PALM BEACH GARDENS FL 33410
Vithalbhai D Dhaduk director FNCB BANCORP, INC., 102 E. DRINKER ST., DUNMORE PA 18512
Neil J Campbell director, officer: Chief Executive Officer 225 CHIMNEY CORNER LANE, SUITE 2001, JUPITER FL 33458
Very Donald Leroy Jr officer: Executive Vice President 4 SILVERWHITE AVENUE, LITTLE SILVER NJ 07739
William Hearl director 448 SALK CIRCLE, GAITHERSBERG MD 20878
Bruce Harmon officer: Chief Financial Officer 316 DEL PRADO BLVD. S., SUITE 204, CAPE CORAL FL 33990
Catherine J. Pachuk officer: Chief Science Officer 1033 N. JEAGA DR, JUPITER FL 33458
Satishchandran Chandrasekhar officer: Chief Operating Officer 167 CARMELA COURT, JUPITER FL 33478

Marizyme Headlines

From GuruFocus

Marizyme is Pleased to Announce the Appointment of David Barthel as CEO

By GuruFocusNews GuruFocusNews 11-16-2021